Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
Panel discussion on the treatment of adolescent and young adult lymphoma patients
Catherine Bollard et al.
Advancing cellular therapies for blood cancers
One size does not fit all: AML subtype treatment approaches
T-cell engaging antibodies: what lessons have we learnt?